ES2046325T3 - Un equipo de ensayo para niveles de adipsina para uso en el diagnostico de anormalidades geneticas o metabolicas. - Google Patents

Un equipo de ensayo para niveles de adipsina para uso en el diagnostico de anormalidades geneticas o metabolicas.

Info

Publication number
ES2046325T3
ES2046325T3 ES198888810211T ES88810211T ES2046325T3 ES 2046325 T3 ES2046325 T3 ES 2046325T3 ES 198888810211 T ES198888810211 T ES 198888810211T ES 88810211 T ES88810211 T ES 88810211T ES 2046325 T3 ES2046325 T3 ES 2046325T3
Authority
ES
Spain
Prior art keywords
genetic
adipsine
diagnosis
levels
adipsin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198888810211T
Other languages
English (en)
Inventor
S. Flier Jeffrey
Bruce M. Spiegelmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Beth Israel Deaconess Medical Center Inc
Original Assignee
Dana Farber Cancer Institute Inc
Beth Israel Deaconess Medical Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc, Beth Israel Deaconess Medical Center Inc filed Critical Dana Farber Cancer Institute Inc
Application granted granted Critical
Publication of ES2046325T3 publication Critical patent/ES2046325T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

METODO PARA DISTINGUIR ENTRE PERSONAS QUE TIENEN METABOLISMOS NORMALES, Y GANAN PESO DEBIDO A SOBREALIMENTACION, DE LAS PERSONAS QUE TIENEN PROPENSION A GANAR PESO DEBIDO A UNA ANORMALIDAD GENETICA, DETECTANDO EL NIVEL DE LA PROTEINA ADIPSINA EN LA SANGRE O EN EL NIVEL DE DNA DE ADIPSINA EN LOS LEUCOCITOS. METODO PARA TRATAR LA ANORMALIDAD DE GANANCIA DE PESO GENETICA MEDIANTE ADMINISTRACION DE CANTIDADES TERAPEUTICAS DE ADIPSINA.
ES198888810211T 1987-04-02 1988-03-30 Un equipo de ensayo para niveles de adipsina para uso en el diagnostico de anormalidades geneticas o metabolicas. Expired - Lifetime ES2046325T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3420387A 1987-04-02 1987-04-02

Publications (1)

Publication Number Publication Date
ES2046325T3 true ES2046325T3 (es) 1994-02-01

Family

ID=21874944

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198888810211T Expired - Lifetime ES2046325T3 (es) 1987-04-02 1988-03-30 Un equipo de ensayo para niveles de adipsina para uso en el diagnostico de anormalidades geneticas o metabolicas.

Country Status (13)

Country Link
EP (2) EP0382720B1 (es)
JP (1) JPH02503229A (es)
AT (1) ATE80465T1 (es)
AU (1) AU606946B2 (es)
DE (1) DE3874543T2 (es)
DK (1) DK675388D0 (es)
ES (1) ES2046325T3 (es)
FI (1) FI894592A7 (es)
GR (1) GR3005716T3 (es)
IL (1) IL85897A0 (es)
NO (1) NO885360L (es)
WO (1) WO1988007681A1 (es)
ZA (1) ZA882288B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2084062A1 (en) * 1990-06-01 1991-12-02 Ginette Serrero Mammalian adipogenic factors
EP1578367A4 (en) * 2002-11-01 2012-05-02 Genentech Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES
US10328131B2 (en) 2014-03-13 2019-06-25 Dana-Farber Cancer Institute, Inc. Compositions and methods for regulating pancreatic beta cell function using adipsin
DE102014107380A1 (de) 2014-05-26 2015-11-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Verfahren zur Diagnose einer durch den alternativen Weg des Komplementsystems vermittelten Krankheit oder eines Risikos hierfür

Also Published As

Publication number Publication date
FI894592L (fi) 1989-09-28
DE3874543D1 (de) 1992-10-15
NO885360L (no) 1989-02-01
DK675388A (da) 1988-12-02
JPH02503229A (ja) 1990-10-04
ZA882288B (en) 1988-12-28
IL85897A0 (en) 1988-09-30
FI894592A0 (fi) 1989-09-28
AU606946B2 (en) 1991-02-21
NO885360D0 (no) 1988-12-01
EP0382720A1 (en) 1990-08-22
ATE80465T1 (de) 1992-09-15
DK675388D0 (da) 1988-12-02
WO1988007681A1 (en) 1988-10-06
AU1591388A (en) 1988-11-02
EP0287509A1 (en) 1988-10-19
EP0382720B1 (en) 1992-09-09
EP0382720A4 (en) 1991-01-02
EP0287509B1 (en) 1992-09-16
GR3005716T3 (es) 1993-06-07
FI894592A7 (fi) 1989-09-28
DE3874543T2 (de) 1993-02-04

Similar Documents

Publication Publication Date Title
ES2150496T3 (es) Cicloalquilimidazopiridinas condensadas.
DE68929551D1 (de) Menschliche DNase
MX9700538A (es) Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para las enfermedades cardiovasculares.
NO964007L (no) Kombinasjoner av trombolytisk aktive proteiner og antikoagulanter samt anvendelse derav
ES2065352T3 (es) Concentrado de proteinas no desnaturalizadas de suero lacteo.
ATE503523T1 (de) Vorrichtung für eine isolierte beckenperfusion
DE3582439D1 (de) Mittel zur behandlung von herzerkrankungen.
FI863971A7 (fi) Farmaseuttinen koostumus käytettäväksi leukopenian hoidossa.
ES2093607T3 (es) Rna bicatenario para la correccion de anomalias en complejos inmunes circulantes y en la funcion de los monocitos.
DE59209196D1 (de) Menschliche il-4 mutantenproteine
MX9205568A (es) Composicion farmaceutica que contiene cantidades de 5-amino-1beta-d-ribofuranosil-imidazol-4-carboxamida.
ES2032922T3 (es) Empleo de los paf-aceter antagonicos para la fabricacion de un medicamento y procedimiento para determinar la eficacia de los mismos.
Horowitz et al. Effects of prenatal exposure to fluoridation on dental caries
DE3773893D1 (de) Synergistische kombination von azelastin und theophyllin oder azelastin und beta-mimetika.
TR199901385T2 (xx) Piperidin t�revleri.
ES2080954T3 (es) Uso de beta-aletina en cultivos de celulas y en terapia.
DK24687A (da) 3-alkoxyflavonderivater samt antiviralt virksomme terapeutiske midler indeholdende disse
ES2053925T3 (es) Una composicion para el tratamiento de pacientes con sindrome de inmunodeficiencia adquirida.
FI894592A0 (fi) Diagnostisering av oeverfloedig fetma foerorsakad av genetisk foerorsakad oeferfloedig fetma.
ES8704903A1 (es) Un metodo para preparar 6-cloro-2-metil-1h-2,3,4,5-tetrahidro-3-benzazepen-n-oxido.
ATE30238T1 (de) N-acylderivate von peptiden, ihre herstellung und verwendung bei der bekaempfung von krankheiten und mittel dafuer.
IT8819079A0 (it) Composizione conciante e sua utilizzazione nei procedimenti di concia e riconcia delle pelli animali.
Drâgan et al. Studies on selenium in top athletes
Udry et al. NLM CURRENT CATALOG AEROSOLS
Schneeberger et al. Long-Term Observation of the Metabolism and Adapted Therapy in Cystine Stone Patients

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 287509

Country of ref document: ES